List of Excipients in Branded Drug FLUOROMETHOLONE OPHTHALMIC SUSPENSION

« Back to Dashboard

Generic Drugs Containing FLUOROMETHOLONE OPHTHALMIC SUSPENSION

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	BENZALKONIUM CHLORIDE
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	EDETATE DISODIUM
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	POLYSORBATE 80
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	POLYVINYL ALCOHOL
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	SODIUM CHLORIDE
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	SODIUM HYDROXIDE
Amneal Pharmaceuticals NY LLC	fluorometholone	60219-1585	SODIUM PHOSPHATE, DIBASIC

What are the Most Frequently-Used Excipients in FLUOROMETHOLONE OPHTHALMIC SUSPENSION?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	EDETATE DISODIUM
1	POLYSORBATE 80
1	POLYVINYL ALCOHOL
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	SODIUM PHOSPHATE, DIBASIC

Fluorometholone Ophthalmic Suspension Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Fluorometholone ophthalmic suspension is a mature topical corticosteroid product with limited active-ingredient exclusivity and substantial room for differentiation through excipient selection, preservative strategy, suspension stability, delivery devices, and packaging. The strongest commercial opportunities are preservative-free unit-dose products, improved shake-and-dose consistency, lower-irritation formulations, and differentiated presentations for chronic or postoperative ophthalmic use.

What is the commercial position of fluorometholone ophthalmic suspension?

Fluorometholone is a topical ophthalmic corticosteroid used to treat steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. The principal marketed suspension strength is 0.1%, with higher-strength presentations historically available in some markets.

The product is commercially mature. Competition is primarily generic and price-driven, while branded products such as FML have established physician recognition. The opportunity is not a conventional new-molecule exclusivity play. It is a formulation, device, supply-chain, and market-segmentation opportunity.

Core product characteristics

Attribute	Commercial relevance
Active ingredient	Fluorometholone
Common dosage form	Ophthalmic suspension
Common strength	0.1%
Therapeutic class	Topical ophthalmic corticosteroid
Route	Topical ocular administration
Primary technical issue	Uniform dose delivery after shaking
Key safety issue	Intraocular pressure elevation and infection risk
Primary regulatory route for a generic	ANDA under section 505(j)
Main differentiation avenues	Preservative-free packaging, particle control, redispersibility, device design, supply reliability

Fluorometholone has a lower tendency to raise intraocular pressure than some more potent ophthalmic corticosteroids, but the risk remains clinically relevant. Product labeling warns about prolonged use, glaucoma, delayed healing, and masking or worsening ocular infection [1].

What excipients are used in fluorometholone ophthalmic suspension?

The excipient system typically combines a wetting agent, viscosity modifier or suspending aid, tonicity adjuster, buffer, chelator, preservative, and purified aqueous vehicle. Exact compositions differ by manufacturer and product presentation.

Functional excipient categories

Excipient category	Typical examples	Technical purpose
Wetting and dispersing agents	Polysorbate 80, tyloxapol, povidone	Improve wetting of hydrophobic fluorometholone particles and reduce aggregation
Suspending or viscosity agents	Hydroxypropyl methylcellulose, povidone, carboxymethylcellulose	Slow sedimentation and support dose uniformity
Tonicity agents	Sodium chloride, glycerin, mannitol	Improve ocular tolerability and osmotic balance
Buffer system	Borate, phosphate, citrate	Control pH and support chemical stability
Chelator	Edetate disodium	Binds trace metals and can improve preservative performance
Preservative	Benzalkonium chloride or alternative systems	Controls microbial growth in multidose containers
pH adjusters	Sodium hydroxide, hydrochloric acid	Set final product pH
Vehicle	Sterile water for injection or purified water processed for ophthalmic use	Continuous phase

Public product labeling for fluorometholone ophthalmic suspensions identifies excipients such as boric acid, edetate disodium, polysorbate 80, sodium chloride, sodium hydroxide, and water in certain presentations. Other products may use different wetting agents, buffers, viscosity modifiers, or preservatives [2,3].

The formulation objective is not to maximize viscosity. Excess viscosity can impair drop formation, increase blurred vision, create bottle-retention problems, and alter the delivered dose. The preferred system provides rapid redispersion, acceptable sedimentation over shelf life, predictable drop size, and minimal ocular irritation.

How should an excipient strategy be designed for fluorometholone suspension?

A successful strategy should treat the product as a particle-engineering and delivery-system problem rather than as a simple aqueous formulation.

1. Control particle size and crystal form

Fluorometholone is a poorly water-soluble corticosteroid. Particle size affects sedimentation, redispersibility, ocular residence, visual blur, and dose consistency. A narrower particle-size distribution can reduce segregation and improve batch-to-batch performance.

Critical development variables include:

• D10, D50, and D90 particle size;
• particle morphology;
• polymorphic form;
• wetting behavior;
• aggregation after sterilization or storage;
• sedimentation volume;
• redispersion time;
• delivered-dose uniformity after specified shaking.

A smaller particle size may improve suspension uniformity but can also increase surface energy and aggregation. The wetting-agent concentration must therefore be optimized with the solid-state properties of the active ingredient.

2. Optimize wetting and dispersion

Polysorbate 80 is a common choice because it improves wetting of hydrophobic drug particles. Tyloxapol and povidone may offer alternative dispersion profiles. The selection should consider:

• particle wetting speed;
• foaming tendency;
• interaction with preservatives;
• peroxide content and oxidative stability;
• extractables and leachables;
• ocular tolerability;
• compatibility with container-closure materials.

A formulation that produces excessive foam during shaking can create dose variability and poor patient acceptance. A low-foam dispersant system may be commercially valuable even when its pharmacology is unchanged.

3. Balance viscosity against drop performance

Suspending agents reduce sedimentation but can make the product difficult to dispense. High viscosity may produce a larger or less consistent drop, increase residual volume in the bottle, and create a prolonged period of blurred vision.

A commercially attractive product should demonstrate:

• short redispersion time;
• no hard cake formation;
• consistent drop mass across bottle orientation;
• stable rheology over temperature;
• acceptable squeeze force;
• limited bottle residual volume;
• no nozzle blockage.

Hydroxypropyl methylcellulose, povidone, and related polymers can be evaluated as single agents or in low-level combinations. The preferred polymer system depends on the target container, dropper geometry, and desired shelf life.

4. Select the preservative strategy by market segment

Benzalkonium chloride is widely used in multidose ophthalmic products, but chronic exposure can damage the ocular surface, particularly in patients with dry eye, epithelial disease, or frequent dosing. A preservative-free presentation can command a higher price and may be preferred in chronic-use or postoperative segments.

Potential approaches include:

• preservative-containing multidose bottles for low-cost retail markets;
• preservative-free unit-dose vials;
• preservative-free multidose systems using a microbial-barrier closure;
• alternative preservatives with lower ocular-surface burden;
• reduced-exposure packaging that limits preservative delivery.

A preservative-free suspension creates technical challenges. Unit-dose packaging increases material, filling, and logistics costs. The formulation must also maintain uniformity through the full use period because the absence of preservative does not eliminate the need for tight microbial controls.

What formulations are protected by patents?

The active ingredient and basic fluorometholone ophthalmic suspension concept are mature technologies. Original compound, composition, and early product patents associated with fluorometholone are no longer expected to provide meaningful U.S. market exclusivity. New patent value would likely arise from a specific, non-obvious combination of:

• particle-size distribution;
• polymorphic form;
• excipient ratios;
• preservative-free suspension architecture;
• multidose microbial-barrier container;
• nozzle or drop-control design;
• manufacturing process;
• improved redispersibility;
• reduced sedimentation or dose variability;
• specific clinical use population.

A patent directed only to the use of a familiar excipient in a conventional fluorometholone suspension would face substantial obviousness risk. Stronger claims would require comparative data showing a measurable technical effect, such as improved delivered-dose uniformity, reduced aggregation, lower irritation, longer stability, or superior performance after repeated dispensing.

Patentability priorities

Candidate claim area	Likely value
New fluorometholone chemical entity	Low, because the molecule is old
Broad ophthalmic suspension claim	Low
Narrow excipient ratio with unexpected stability	Moderate
Preservative-free multidose system	Moderate to high
Specific particle-size and rheology profile	Moderate
Device-plus-formulation combination	Moderate to high
Manufacturing process that prevents aggregation	Moderate
Method of reducing preservative exposure	Moderate
New indication without clinical differentiation	Limited

When does fluorometholone ophthalmic suspension lose exclusivity?

Fluorometholone has no meaningful remaining new-molecule exclusivity in the United States. The relevant commercial barriers are regulatory approval, product quality, manufacturing scale, physician familiarity, and channel access rather than basic active-ingredient protection.

For a new generic, the key regulatory pathway is generally an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. For ophthalmic suspensions, the development package must address more than assay and appearance. The applicant must control particle size, polymorphism, viscosity, pH, osmolality, preservative content, microbial quality, and delivered-dose performance.

A materially different formulation may require a 505(b)(2) application rather than a conventional ANDA. This route may be appropriate for a preservative-free product, a novel multidose container, a different strength, or a formulation with clinically meaningful differences from the reference product [4].

What is the Orange Book status of fluorometholone ophthalmic suspension?

The Orange Book is the controlling source for current reference listed drug designations, approved drug products, therapeutic equivalence codes, patent listings, and exclusivity information [5]. For a mature fluorometholone ophthalmic suspension, the commercial assessment should focus on:

• the applicable reference listed drug;
• the precise strength and dosage form;
• whether the reference is a suspension rather than a solution;
• the therapeutic equivalence code for each approved generic;
• any current listed patents or exclusivity;
• the status of discontinued or withdrawn products;
• whether the intended product requires an ANDA or 505(b)(2) pathway.

A generic suspension cannot assume that a fluorometholone solution, ointment, or different strength is an interchangeable reference. Dosage form, particle behavior, strength, and container performance matter.

Which companies are challenging the fluorometholone market?

The market is supplied by generic ophthalmic manufacturers, specialty ophthalmology companies, contract manufacturers, and branded-product owners. Competition typically occurs through:

• low-cost 5 mL multidose bottles;
• hospital and group-purchasing contracts;
• retail generic substitution;
• branded-generic positioning;
• preservative-free presentations;
• supply reliability during ophthalmic shortages;
• combination products and adjacent corticosteroid products.

The principal competitive set includes fluorometholone products from the original branded franchise and multiple generic manufacturers. Competitive intensity is highest for conventional 0.1% multidose suspension. It is lower for preservative-free products, specialty packaging, and presentations designed for chronic ocular-surface disease.

What generic entry risks exist for fluorometholone suspension?

Generic entry risk is high for an undifferentiated product and lower for a technically differentiated product.

High-risk commercial profile

• Conventional 0.1% multidose bottle;
• standard excipient system;
• no device differentiation;
• dependence on one manufacturing site;
• no supply advantage;
• price-based launch strategy;
• limited pharmacy or institutional contracting.

Lower-risk commercial profile

• Preservative-free unit-dose suspension;
• improved redispersion and dose consistency;
• validated low-foam formulation;
• proprietary drop-control container;
• reliable supply during shortages;
• pediatric or postoperative packaging;
• regional registration strategy outside the United States;
• formulation patent supported by comparative performance data.

Because basic product exclusivity is weak, a conventional generic may launch without encountering a meaningful patent barrier. The principal risks are approval delay, manufacturing deficiencies, failure to match suspension performance, and inability to secure profitable reimbursement.

What commercial opportunities exist for fluorometholone excipient innovation?

Preservative-free ophthalmic suspension

This is the clearest premium opportunity. It targets patients with dry eye, chronic inflammatory disease, recurrent topical therapy, or sensitivity to benzalkonium chloride. Unit-dose packaging is the most straightforward approach, while a multidose preservative-free system could command stronger differentiation.

Improved shake-and-dose performance

Many ophthalmic suspensions require shaking before use. A formulation that redistributes rapidly and maintains dose uniformity after incomplete or inconsistent shaking could support a clinically relevant product claim, subject to regulatory substantiation.

Low-irritation excipient system

A formulation with reduced surfactant, lower preservative exposure, and optimized pH and osmolality may be positioned for ocular-surface tolerability. Human tolerability data would strengthen the commercial case.

Device-enabled delivery

A controlled-drop bottle can reduce overdosing, improve usability for older patients, and reduce waste. Device claims may create protection that is harder to design around than a basic excipient composition.

Global access products

In price-sensitive markets, the opportunity may be a robust, low-cost formulation with a simple bottle, stable supply, and limited excipient complexity. In higher-income markets, the opportunity is more likely to involve preservative-free delivery and premium packaging.

How does fluorometholone compare with other ophthalmic corticosteroids?

Product class	Relative commercial position	Differentiation pressure
Fluorometholone suspension	Mature, lower-cost corticosteroid	High
Loteprednol suspension or gel	Premium, ester-based steroid positioning	Moderate to high
Prednisolone acetate suspension	Established, widely used steroid	High
Dexamethasone suspension or solution	Broad generic competition	High
Difluprednate emulsion	Higher-potency premium product	Moderate
Steroid-antibiotic combinations	Convenience-driven products	Moderate

Fluorometholone can compete through ocular-surface tolerability and lower-cost positioning, but it must overcome the availability of established alternatives. The strongest product concept combines the known clinical profile of fluorometholone with a formulation benefit that physicians and patients can recognize.

What litigation and settlement issues affect fluorometholone?

No major current patent-litigation barrier should be assumed for the legacy fluorometholone molecule or a conventional suspension. The relevant litigation risk would arise from a newly patented formulation, device, manufacturing process, or branded reformulation.

A new entrant should evaluate:

• Orange Book patent listings for the selected reference product;
• Paragraph IV certifications for any listed patents;
• patent families covering preservative-free suspension systems;
• device patents covering multidose ophthalmic dispensers;
• formulation patents owned by specialty ophthalmology companies;
• supplier rights for proprietary polymers or container systems;
• freedom to operate in the United States, Europe, Japan, and major emerging markets.

Paragraph IV litigation is more likely where the proposed product relies on a recently developed formulation or device than where it copies an established generic suspension.

Key Takeaways

1. Fluorometholone ophthalmic suspension is a mature, largely generic market with limited remaining basic exclusivity.
2. Excipient strategy should focus on particle wetting, redispersibility, sedimentation control, drop uniformity, and ocular tolerability.
3. Preservative-free unit-dose or multidose products offer the strongest premium opportunity.
4. The most defensible intellectual property is likely to cover a specific formulation, device, particle profile, or manufacturing process.
5. Conventional 0.1% multidose products face high generic and price competition.
6. ANDA development is generally appropriate for a pharmaceutically equivalent product, while materially different presentations may require a 505(b)(2) pathway.
7. Manufacturing reliability and device performance may create more commercial value than broad composition claims.

Frequently Asked Questions

Can fluorometholone ophthalmic suspension be formulated without benzalkonium chloride?

Yes. A preservative-free unit-dose product is the most direct approach. A preservative-free multidose product requires a validated microbial-barrier container and a manufacturing process that supports sterility throughout the labeled use period.

Which excipient most improves fluorometholone suspension stability?

No single excipient determines stability. Performance usually depends on the interaction among the wetting agent, suspending polymer, particle-size distribution, pH, ionic strength, and container system.

Is fluorometholone suspension eligible for an ANDA?

A product that matches the reference product in active ingredient, strength, dosage form, route, and relevant quality attributes may be suitable for an ANDA. A materially different formulation or delivery system may require a 505(b)(2) application.

Can a fluorometholone formulation patent block generic entry?

A new patent can create an entry barrier if it covers a commercially necessary formulation, device, or process and survives validity and infringement challenges. Legacy fluorometholone composition patents do not generally provide a practical barrier to modern generic entry.

What is the best premium product concept for fluorometholone?

A preservative-free suspension in a low-residual-volume, controlled-drop container is the strongest premium concept. Its value would increase if comparative data show better redispersion, dose consistency, ocular tolerability, or patient usability.

References

1. DailyMed. (n.d.). Fluorometholone ophthalmic suspension prescribing information. U.S. National Library of Medicine.

2. DailyMed. (n.d.). FML fluorometholone ophthalmic suspension prescribing information. U.S. National Library of Medicine.

3. DailyMed. (n.d.). Fluorometholone ophthalmic suspension, USP, 0.1% prescribing information. U.S. National Library of Medicine.

4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

6. United States Pharmacopeia. (2024). General chapter <771> ophthalmic products. U.S. Pharmacopeial Convention.